Dr. Julie Ann Mayer has held progressive scientific and leadership roles spanning R&D and Operations at several molecular diagnostics companies, including NeoGenomics Laboratories, Biocept Inc., and Navigate BioPharma Services (a Novartis subsidiary). She has extensive precision medicine experience, having developed, validated, and launched >50 diagnostic assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories. Before joining industry, Dr. Mayer received her post-doctoral training in translational breast cancer research at Baylor College of Medicine and in clinical cancer prevention at MD Anderson Cancer Center and obtained her Ph.D in Pathology from the University of Southern California.